Clinical Trials Industry News More

41. TransMolecular's ¹³¹I-Tm601 Shown To Improve Survival In Recurrent Malignant Glioma 10/26/2009

    TransMolecular, Inc., a developer of innovative oncology drugs through targeted delivery technologies, recently announced final results from its Phase 2 clinical study comparing the toxicity and overall survival of three versus six intracavitary injections of its anti-cancer compound ¹³¹I-TM601 in the treatment of recurrent malignant glioma.

42. Surface Dissolution Imaging Gives Insight Into Bioavailability 10/21/2009
    Paraytec has announced that it will be demonstrating an exciting new tool for surface dissolution imaging - the ActiPix SDI300 at the 2009 American Association for Pharmaceutical Scientists (AAPS) meeting in Los Angeles, CA.
43. Transparent Inc. To Introduce Cell-Able, A Unique Human Hepatocyte Array, To U.S. Market At ISSX Meeting 10/20/2009
    Transparent, Inc., a bio-venture business headquartered here, announced recently that it will be introducing Cell-able, a human hepatocyte array kit that has the potential to reduce drug development costs and time-to-market for pharmaceutical companies, at its exhibit at the annual meeting of the International Society for the Study of Xenobiotics in Baltimore, Maryland, October 18-22.
44. ACTEMRA Inhibits Progression Of Joint Destruction In RA Patients By Over 80% Compared To Methotrexate Alone 10/20/2009
    Two-year data from the LITHE study, being presented at the American College of Rheumatology, show that, with long-term use, patients with rheumatoid arthritis treated with ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) plus methotrexate (MTX) suffered 81% less damage to their joints compared to those treated with MTX, the current standard therapy, alone1. For patients, this means that their joint damage is significantly reduced, and that they can therefore continue to enjoy their lives without the evolving disability usually associated with the disease.
45. FDA Approves GARDASIL® For Use In Boys And Young Men 10/16/2009
    Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for use in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.
46. World Courier Triples Clinical Trial Storage Capacity Worldwide With Two New Facilities And Client-Driven Expansion 10/15/2009
    World Courier is pleased to announce the opening of its newest purpose-driven investigational drug storage facilities in Melbourne (Australia) and Johannesburg (South Africa), bringing its network of GMP (Good Manufacturing Practice)-compliant clinical trial depots to a total of 11 worldwide and providing cost-effective logistical access to two continents critical to the global pharmaceutical industry.
47. Two Phase III Studies Of Lucentis Show Early And Sustained Improvement In Vision In Patients With Retinal Vein Occlusion 10/12/2009
    Genentech, Inc., a wholly-owned member of the Roche Group, recently announced results from two Phase III studies of Lucentis (ranibizumab injection) in macular edema due to retinal vein occlusion (RVO), which showed, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections. Results from both trials were presented today at the Retina Congress 2009 meeting.
48. NextPharma Technologies Partners With CARBOGEN AMCIS In Alliance Which Combines Investigational Medicinal Product And Active Pharmaceutical Ingredient Services For Highly Potent Active Pharmaceutical Ingredients 10/8/2009
    NextPharma, the leading European provider of product development, contract manufacturing and cold chain and logistics outsourcing services to the pharmaceutical and biotechnology industries, is pleased to announce that it has entered into an agreement with CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, to provide customers with seamless development services covering highly potent pharmaceutical ingredient (APIs) and Investigational Medicinal Products (IMPs) for clinical trials.
49. Specialist UK Distributor Of Analytical & Life Science Instrumentation 10/8/2009
    Benefiting from over 25 years of experience in the analytical instrumentation and life science industry - Dorton Analytical Ltd - a new distribution company serving the UK scientific community was formed on the 1st September, 2009.
50. Boehringer Ingelheim`s Diabetes Pipeline Continues To Advance As The Company Announces Conclusion Of Robust Phase III Pivotal Trials Programme For Linagliptin 9/30/2009
    Following the release of linagliptin Phase II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal Phase III clinical trials.